Targeting the Metabolic Microenvironment of Tumors

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 63-107

  Bailey, Kate M ^a,b   Wojtkowiak, Jonathan W ^a   Hashim, Arig Ibrahim ^a   Gillies, Robert J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Tumor acidosis; Tumor hypoxia; Tumor metabolism; Tumor microenvironment; Warburg effect

Indexed keywords

3 (3 PYRIDINYL) 1 (4 PYRIDINYL) 2 PROPEN 1 ONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; 6 PHOSPHOFRUCTOKINASE; ANTINEOPLASTIC AGENT; APAZIQUONE; BANOXANTRONE; BORTEZOMIB; BROMOPYRUVIC ACID; CYTOCHALASIN B; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE; DICHLOROACETIC ACID; EVEROLIMUS; EZN 2968; GALLOFLAVIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GOSSYPOL; HEXOKINASE; LACTATE DEHYDROGENASE; LONIDAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PACLITAXEL; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE; RAPAMYCIN; STF 083010; TEMSIROLIMUS; TIRAPAZAMINE; TOPOTECAN; UNCLASSIFIED DRUG;

ACIDIFICATION; ACIDOSIS; ADVANCED CANCER; ARTICLE; BREAST CANCER; CARCINOMA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG HALF LIFE; ELECTRON PARAMAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; GLUCOSE METABOLISM; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LACTIC ACIDOSIS; LEUKEMIA; LIVER METASTASIS; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL NEUROPATHY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTON TRANSPORT; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; UPREGULATION; UTERINE CERVIX CANCER; VASCULARIZATION; WEIGHT REDUCTION;

EID: 84865835733     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00004-X     Document Type: Chapter

References (247)

1. Adachi E., Tannock I.F. The effects of vasodilating drugs on pH in tumors. [Research Support, Non-U.S. Gov't]. Oncology Research 1999, 11(4):179-185.
2. Akter S., Clem B.F., Lee H.J., Chesney J., Bae Y. Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors. Pharmaceutical Research 2011.
3. Akter S., Clem B.F., Lee H.J., Chesney J., Bae Y. Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors. Pharmaceutical Research 2012, 29(3):847-855.
4. Altenberg B., Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Research Support, Non-U.S. Gov't. Genomics 2004, 84(6):1014-1020.
5. Anderson R.F., Shinde S.S., Hay M.P., Gamage S.A., Denny W.A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. Journal of the American Chemical Society 2003, 125(3):748-756.
6. Asada K., Miyamoto K., Fukutomi T., Tsuda H., Yagi Y., Wakazono K., et al. Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. [Research Support, Non-U.S. Gov't]. Oncology 2003, 64(4):380-388.
7. Atsumi T., Chesney J., Metz C., Leng L., Donnelly S., Makita Z., et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Research 2002, 62(20):5881-5887.
8. Aulitzky W.E., Aulitzky W., Gastl G., Lanske B., Reitter J., Frick J., et al. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. Journal of Interferon Cytokine Research 1989, 9(4):425-433.
9. Ayala F.R., Rocha R.M., Carvalho K.C., Carvalho A.L., da Cunha I.W., Lourenco S.V., et al. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. [Research Support, Non-U.S. Gov't]. Molecules 2010, 15(4):2374-2387.
10. Ayral-Kaloustian S., Gu J., Lucas J., Cinque M., Gaydos C., Zask A., et al. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. Journal of Medicinal Chemistry 2010, 53(1):452-459.
11. Back S.H., Lee K., Vink E., Kaufman R.J. Cytoplasmic IRE1alpha-mediated XBP1 mRNA splicing in the absence of nuclear processing and endoplasmic reticulum stress. [Research Support, N.I.H., Extramural]. Journal of Biological Chemistry 2006, 281(27):18691-18706.
12. Baker M.A., Zeman E.M., Hirst V.K., Brown J.M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Research 1988, 48(21):5947-5952.
13. Belfi C.A., Paul C.R., Shan S., Ngo F.Q. Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. International Journal of Radiation Oncology, Biology, Physics 1994, 29(3):473-479.
14. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Research 2010, 70(6):2465-2475.
15. Ben Sahra I., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27(25):3576-3586.
16. Bennewith K.L., Raleigh J.A., Durand R.E. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Research 2002, 62(23):6827-6830.
17. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. [Research Support, Non-U.S. Gov't]. Cell 2006, 126(1):107-120.
18. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. [Research Support, N.I.H., Extramural]. Nature 2006, 442(7104):779-785.
19. Bi M., Naczki C., Koritzinsky M., Fels D., Blais J., Hu N., et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. [Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.]. EMBO Journal 2005, 24(19):3470-3481.
20. Birnbaum M.J., Haspel H.C., Rosen O.M. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987, 235(4795):1495-1498.
21. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research 2000, 60(17):4693-4696.
22. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11(1):37-51.
23. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97(6):1573-1581.
24. Bos R., van Der Hoeven J.J., van Der Wall E., van Der Groep P., van Diest P.J., Comans E.F., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. [Research Support, Non-U.S. Gov't]. Journal of Clinical Oncology 2002, 20(2):379-387.
25. Bosca L., Mojena M., Ghysdael J., Rousseau G.G., Hue L. Expression of the v-src or v-fps oncogene increases fructose 2,6-bisphosphate in chick-embryo fibroblasts. Novel mechanism for the stimulation of glycolysis by retroviruses. Biochemical Journal 1986, 236(2):595-599.
26. Bowker-Kinley M.M., Davis W.I., Wu P., Harris R.A., Popov K.M. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochemical Journal 1998, 329(Pt 1):191-196.
27. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29(2):254-258.
28. Brawer M.K. Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Reviews in Urology 2005, 7(Suppl. 7):S21-S26.
29. Bueno V., Binet I., Steger U., Bundick R., Ferguson D., Murray C., et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. [Research Support, Non-U.S. Gov't]. Transplantation 2007, 84(9):1204-1207.
30. Burant C.F., Bell G.I. Mammalian facilitative glucose transporters: evidence for similar substrate recognition sites in functionally monomeric proteins. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Biochemistry 1992, 31(42):10414-10420.
31. Cantuaria G., Fagotti A., Ferrandina G., Magalhaes A., Nadji M., Angioli R., et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001, 92(5):1144-1150.
32. Cao W., Yacoub S., Shiverick K.T., Namiki K., Sakai Y., Porvasnik S., et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 2008, 68(11):1223-1231.
33. Chan D.A., Sutphin P.D., Nguyen P., Turcotte S., Lai E.W., Banh A., et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Science Translational Medicine 2011, 3(94):94ra70.
34. Cheong J.H., Park E.S., Liang J., Dennison J.B., Tsavachidou D., Nguyen-Charles C., et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Molecular Cancer Therapeutics 2011, 10(12):2350-2362.
35. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452(7184):230-233.
36. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nature Reviews Cancer 2010, 10(7):505-514.
37. Cirstea D., Hideshima T., Rodig S., Santo L., Pozzi S., Vallet S., et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Molecular Cancer Therapeutics 2010, 9(4):963-975.
38. Clem B., Telang S., Clem A., Yalcin A., Meier J., Simmons A., et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Molecular Cancer Therapeutics 2008, 7(1):110-120.
39. Coleman M.C., Asbury C.R., Daniels D., Du J., Aykin-Burns N., Smith B.J., et al. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radicical Biology and Medicine 2008, 44(3):322-331.
40. Connolly E., Braunstein S., Formenti S., Schneider R.J. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. Molecular and Cellular Biology 2006, 26(10):3955-3965.
41. Dachs G.U., Steele A.J., Coralli C., Kanthou C., Brooks A.C., Gunningham S.P., et al. Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 2006, 6:280.
42. Dazert E., Hall M.N. mTOR signaling in disease. [Research Support, Non-U.S. Gov't Review]. Current Opinion in Cell Biology 2011, 23(6):744-755.
43. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer 2008, 8(6):425-437.
44. Ditonno P., Battaglia M., Selvaggio O., Garofalo L., Lorusso V., Selvaggi F.P. Clinical evidence supporting the role of lonidamine for the treatment of BPH. Reviews in Urology 2005, 7(Suppl. 7):S27-S33.
45. Dong B., Niwa M., Walter P., Silverman R.H. Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. RNA 2001, 7(3):361-373.
46. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 2007, 67(22):10804-10812.
47. Duan J.X., Jiao H., Kaizerman J., Stanton T., Evans J.W., Lan L., et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. Journal of Medicinal Chemistry 2008, 51(8):2412-2420.
48. Elekes K., Helyes Z., Kereskai L., Sandor K., Pinter E., Pozsgai G., et al. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. European Journal of Pharmacology 2008, 578(2-3):313-322.
49. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330(7503):1304-1305.
50. Evans J.W., Chernikova S.B., Kachnic L.A., Banath J.P., Sordet O., Delahoussaye Y.M., et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Research 2008, 68(1):257-265.
51. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9(6):425-434.
52. Fels D.R., Ye J., Segan A.T., Kridel S.J., Spiotto M., Olson M., et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Research 2008, 68(22):9323-9330.
53. Firth J.D., Ebert B.L., Ratcliffe P.J. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. [Research Support, Non-U.S. Gov't]. Journal of Biological Chemistry 1995, 270(36):21021-21027.
54. Flier J.S., Mueckler M.M., Usher P., Lodish H.F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235(4795):1492-1495.
55. Floridi A., Lehninger A.L. Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Archives of Biochemistry and Biophysics 1983, 226(1):73-83.
56. Floridi A., Paggi M.G., Marcante M.L., Silvestrini B., Caputo A., De Martino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. Journal of National Cancer Institute 1981, 66(3):497-499.
57. Gabardi S., Baroletti S.A. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010, 30(10):1044-1056.
58. Gallagher F.A., Kettunen M.I., Day S.E., Hu D.E., Ardenkjaer-Larsen J.H., Zandt R., et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008, 453(7197):940-943.
59. Gallagher R., Hughes C.M., Murray M.M., Friery O.P., Patterson L.H., Hirst D.G., et al. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. [Comparative Study Research Support, Non-U.S. Gov't]. British Journal of Cancer 2001, 85(4):625-629.
60. Ganjoo K.N., Cranmer L.D., Butrynski J.E., Rushing D., Adkins D., Okuno S.H., et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011, 80(1-2):50-56.
61. Garcia-Martin M.L., Martinez G.V., Raghunand N., Sherry A.D., Zhang S., Gillies R.J. High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magnetic Resonance in Medicine 2006, 55(2):309-315.
62. Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis. [Review]. Nature Reviews Cancer 2008, 8(1):56-61.
63. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. British Journal of Cancer 2001, 85(6):881-890.
64. Gillies R.J., Morse D.L. In vivo magnetic resonance spectroscopy in cancer. Annual Review of Biomedical Engineering 2005, 7:287-326.
65. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. Journal of Nuclear Medicine 2008, 49(Suppl. 2):24S-42S.
66. Gillies R.J., Schornack P.A., Secomb T.W., Raghunand N. Causes and effects of heterogeneous perfusion in tumors. [Research Support, U.S. Gov't, P.H.S. Review]. Neoplasia 1999, 1(3):197-207.
67. Goel A., Mathupala S.P., Pedersen P.L. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. Journal of Biological Chemistry 2003, 278(17):15333-15340.
68. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews 2011, 91(3):1071-1121.
69. Goldman R.D., Kaplan N.O., Hall T.C. Lactic dehydrogenase in human neoplastic tissues. Cancer Research 1964, 24:389-399.
70. Gould G.W., Thomas H.M., Jess T.J., Bell G.I. Expression of human glucose transporters in Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms. Biochemistry 1991, 30(21):5139-5145.
71. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. [Research Support, Non-U.S. Gov't P.H.S.]. Nature 1996, 379(6560):88-91.
72. Granchi C., Roy S., Giacomelli C., Macchia M., Tuccinardi T., Martinelli A., et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. Journal of Medicinal Chemistry 2011, 54(6):1599-1612.
73. Greenberg R., Haddad R., Kashtan H., Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. Journal of Laboratory and Clinical Medicine 2000, 135(2):112-121.
74. Greenberger L.M., Horak I.D., Filpula D., Sapra P., Westergaard M., Frydenlund H.F., et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Molecular Cancer Therapeutics 2008, 7(11):3598-3608.
75. Griffiths J.R. Are cancer cells acidic?. British Journal of Cancer 1991, 64(3):425-427.
76. Grinstein S., Rotin D., Mason M.J. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. [Research Support, Non-U.S. Gov't Review]. Biochimica et Biophysica Acta 1989, 988(1):73-97.
77. Han D., Lerner A.G., Vande Walle L., Upton J.P., Xu W., Hagen A., et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. [Research support, N.I.H., extramural research support, Non-U.S. Gov't]. Cell 2009, 138(3):562-575.
78. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
79. Hashim A.I., Zhang X., Wojtkowiak J.W., Martinez G.V., Gillies R.J. Imaging pH and metastasis. [Review]. NMR in Biomedicine 2011, 24(6):582-591.
80. Hatanaka M. Transport of sugars in tumor cell membranes. Biochimica et Biophysica Acta 1974, 355(1):77-104.
81. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253(5022):905-909.
82. Hendricksen K., van der Heijden A.G., Cornel E.B., Vergunst H., de Reijke T.M., van Boven E., et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World Journal of Urology 2009, 27(3):337-342.
83. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology 2009, 27(23):3822-3829.
84. Hicks K.O., Fleming Y., Siim B.G., Koch C.J., Wilson W.R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. International Journal of Radiation Oncology, Biology, Physics 1998, 42(3):641-649.
85. Hicks K.O., Siim B.G., Jaiswal J.K., Pruijn F.B., Fraser A.M., Patel R., et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clinical Cancer Research 2010, 16(20):4946-4957.
86. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. [Research support, Non-U.S. Gov't Review]. Journal of National Cancer Institute 2001, 93(4):266-276.
87. Holness M.J., Sugden M.C. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. [Research Support, Non-U.S. Gov't Review]. Biochemical Society Transactions 2003, 31(Pt 6):1143-1151.
88. Horsman M.R., Christensen K.L., Overgaard J. Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure. [Research support, Non-U.S. Gov't]. International Journal of Radiation Oncology, Biology, Physics 1992, 22(3):455-458.
89. Houchens D.P., Ovejera A.A., Riblet S.M., Slagel D.E. Human brain tumor xenografts in nude mice as a chemotherapy model. European Journal of Cancer & Clinical Oncology 1983, 19(6):799-805.
90. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. [Research support, U.S. Gov't, P.H.S.]. Journal of Biological Chemistry 1985, 260(27):14873-14878.
91. Hu J., Handisides D.R., Van Valckenborgh E., De Raeve H., Menu E., Vande Broek I., et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010, 116(9):1524-1527.
92. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 2007, 356(22):2271-2281.
93. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49(12):2063-2069.
94. Ibrahim Hashim A., Cornnell H.H., Coelho Ribeiro Mde L., Abrahams D., Cunningham J., Lloyd M., et al. Reduction of metastasis using a non-volatile buffer. Clinical and Experimental Metastasis 2011, 28(8):841-849.
95. Ikezoe T., Nishioka C., Bandobashi K., Yang Y., Kuwayama Y., Adachi Y., et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leukemia Research 2007, 31(5):673-682.
96. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115(5):577-590.
97. Iyer V.N., Szybalski W. Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science 1964, 145(3627):55-58.
98. Ibrahim-Hashim A., Wojtkowiak J.W., de Lourdes Coelho Ribeiro M., Estrella V., Bailey K.M., et al. Free Base Lysine Increases Survival and Reduces Metastasis in Prostate Cancer Model. Journal of Cancer Science and Therapy S1 2011.
99. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. [Research Support, Non-U.S. Gov't]. Science 2001, 292(5516):468-472.
100. Jahde E., Glusenkamp K.H., Rajewsky M.F. Protection of cultured malignant cells from mitoxantrone cytotoxicity by low extracellular pH: a possible mechanism for chemoresistance in vivo. European Journal Cancer 1990, 26(2):101-106.
101. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine 2001, 7(9):987-989.
102. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
103. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005, 7(5):475-485.
104. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. [Research support, N.I.H., extramural research support, Non-U.S. Gov't Review]. FEBS Letters 2010, 584(7):1287-1295.
105. Kaper F., Dornhoefer N., Giaccia A.J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Cancer Research 2006, 66(3):1561-1569.
106. Kasahara M., Hinkle P.C. Reconstitution and purification of the D-glucose transporter from human erythrocytes. Journal of Biological Chemistry 1977, 252(20):7384-7390.
107. Kauppinen R.A., Nicholls D.G. Synaptosomal bioenergetics. The role of glycolysis, pyruvate oxidation and responses to hypoglycaemia. [In Vitro Research Support, Non-U.S. Gov't]. European Journal of Biochemistry 1986, 158(1):159-165.
108. Kelloff G.J., Hoffman J.M., Johnson B., Scher H.I., Siegel B.A., Cheng E.Y., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clinical Cancer Research 2005, 11(8):2785-2808.
109. Kim Y., Lin Q., Glazer P.M., Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Current Molecular Medicine 2009, 9(4):425-434.
110. Knoechel T.R., Tucker A.D., Robinson C.M., Phillips C., Taylor W., Bungay P.J., et al. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry 2006, 45(2):402-415.
111. Ko Y.H., Pedersen P.L., Geschwind J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Letters 2001, 173(1):83-91.
112. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 2008, 7(1):90-100.
113. Kole H.K., Resnick R.J., Van Doren M., Racker E. Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. Archives of Biochemistry and Biophysics 1991, 286(2):586-590.
114. Korennykh A.V., Egea P.F., Korostelev A.A., Finer-Moore J., Zhang C., Shokat K.M., et al. The unfolded protein response signals through high-order assembly of Ire1. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Nature 2009, 457(7230):687-693.
115. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Molecular and Cellular Biology 2002, 22(21):7405-7416.
116. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13(6):472-482.
117. Kummar S., Raffeld M., Juwara L., Horneffer Y., Strassberger A., Allen D., et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. [Clinical Trial, Phase I research support, N.I.H., Extramural]. Clinical Cancer Research 2011, 17(15):5123-5131.
118. Kurtoglu M., Maher J.C., Lampidis T.J. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxidants & Redox Signaling 2007, 9(9):1383-1390.
119. Kyle A.H., Minchinton A.I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemotherapy and Pharmacology 1999, 43(3):213-220.
120. Lampidis T.J., Kurtoglu M., Maher J.C., Liu H., Krishan A., Sheft V., et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemotherapy and Pharmacology 2006, 58(6):725-734.
121. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. [Research support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences U S A 2010, 107(5):2037-2042.
122. Le Q.T., McCoy J., Williamson S., Ryu J., Gaspar L.E., Edelman M.J., et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clinical Cancer Research 2004, 10(16):5418-5424.
123. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Proceedings of the National Academy of Sciences U S A 2003, 100(17):9946-9951.
124. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. [Research support, Non-U.S. Gov't]. Cancer Research 2005, 65(16):7249-7258.
125. Li Y., Wang Y., Kim E., Beemiller P., Wang C.Y., Swanson J., et al. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. [Research support, N.I.H., Extramural research support, U.S. Gov't, Non-P.H.S.]. Journal of Biological Chemistry 2007, 282(49):35803-35813.
126. Li Y.C., Fung K.P., Kwok T.T., Lee C.Y., Suen Y.K., Kong S.K. Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Science 2002, 71(23):2729-2740.
127. Lin X., Zhang F., Bradbury C.M., Kaushal A., Li L., Spitz D.R., et al. 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Research 2003, 63(12):3413-3417.
128. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Molecular Cell 2006, 21(4):521-531.
129. Lou Y., McDonald P.C., Oloumi A., Chia S., Ostlund C., Ahmadi A., et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Research 2011, 71(9):3364-3376.
130. Luciani F., Spada M., De Milito A., Molinari A., Rivoltini L., Montinaro A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. Journal of National Cancer Institute 2004, 96(22):1702-1713.
131. Mathupala S.P., Heese C., Pedersen P.L. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. Journal of Biological Chemistry 1997, 272(36):22776-22780.
132. Matsumoto S., Batra S., Saito K., Yasui H., Choudhuri R., Gadisetti C., et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Research 2011, 71(20):6350-6359.
133. Matsumoto S., Yasui H., Mitchell J.B., Krishna M.C. Imaging cycling tumor hypoxia. Cancer Research 2010, 70(24):10019-10023.
134. McKeage M.J., Gu Y., Wilson W.R., Hill A., Amies K., Melink T.J., et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer 2011, 11:432.
135. Meloche H.P., Luczak M.A., Wurster J.M. The substrate analog, bromopyruvate, as both a substrate and alkylating agent for 2-keto-3-deoxy-6-phosphogluconic aldolase. Kinetic and stereochemical studies. Journal of Biological Chemistry 1972, 247(13):4186-4191.
136. Meng F., Evans J.W., Bhupathi D., Banica M., Lan L., Lorente G., et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Molecular Cancer Therapeutics 2012.
137. Michelakis E.D., Sutendra G., Dromparis P., Webster L., Haromy A., Niven E., et al. Metabolic modulation of glioblastoma with dichloroacetate. Science Translational Medicine 2010, 2(31):31ra34.
138. Milane L., Duan Z., Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Molecular Pharmacology 2011, 8(1):185-203.
139. Milane L., Duan Z., Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 2011, 6(9):e24075.
140. Mitchell D.C., Bryan B.A. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. [Review]. Journal of Cellular Biochemistry 2010, 111(3):543-553.
141. Moellering R.E., Black K.C., Krishnamurty C., Baggett B.K., Stafford P., Rain M., et al. Acid treatment of melanoma cells selects for invasive phenotypes. Clinical and Experimental Metastasis 2008, 25(4):411-425.
142. Mohanti B.K., Rath G.K., Anantha N., Kannan V., Das B.S., Chandramouli B.A., et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. International Journal of Radiation Oncology, Biology, Physics 1996, 35(1):103-111.
143. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-456.
144. Nakano A., Tsuji D., Miki H., Cui Q., El Sayed S.M., Ikegame A., et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 2011, 6(11):e27222.
145. Nawrocki S.T., Carew J.S., Dunner K., Boise L.H., Chiao P.J., Huang P., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Cancer Research 2005, 65(24):11510-11519.
146. Neri D., Supuran C.T. Interfering with pH regulation in tumours as a therapeutic strategy. [Research Support, Non-U.S. Gov't Review]. Nature Reviews Drug Discovery 2011, 10(10):767-777.
147. Nock S., Gonzalez T.N., Sidrauski C., Niwa M., Walter P. Purification and activity assays of the catalytic domains of the kinase/endoribonuclease Ire1p from Saccharomyces cerevisiae. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Methods in Enzymology 2001, 342:3-10.
148. Nordsmark M., Maxwell R.J., Wood P.J., Stratford I.J., Adams G.E., Overgaard J., et al. Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy. [Research Support, Non-U.S. Gov't]. British Journal of Cancer Supplement 1996, 27:S232-235.
149. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. [Research Support, Non-U.S. Gov't]. Nature Cell Biology 2000, 2(7):423-427.
150. Okunieff P., Kallinowski F., Vaupel P., Neuringer L.J. Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Journal of National Cancer Institute 1988, 80(10):745-750.
151. Osada R., Horiuchi A., Kikuchi N., Yoshida J., Hayashi A., Ota M., et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. [Research support, Non-U.S. Gov't]. Human Pathology 2007, 38(9):1310-1320.
152. Owa T., Yoshino H., Okauchi T., Yoshimatsu K., Ozawa Y., Sugi N.H., et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. Journal of Medicinal Chemistry 1999, 42(19):3789-3799.
153. Pacheco-Torres J., Lopez-Larrubia P., Ballesteros P., Cerdan S. Imaging tumor hypoxia by magnetic resonance methods. [Research support, Non-U.S. Gov't review]. NMR in Biomedicine 2011, 24(1):1-16.
154. Palayoor S.T., Mitchell J.B., Cerna D., Degraff W., John-Aryankalayil M., Coleman C.N. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. International Journal of Cancer 2008, 123(10):2430-2437.
155. Papadopoulos K.P., Goel S., Beeram M., Wong A., Desai K., Haigentz M., et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. [Clinical Trial, Phase I Research support, Non-U.S. Gov't]. Clinical Cancer Research 2008, 14(21):7110-7115.
156. Papandreou I., Denko N.C., Olson M., Van Melckebeke H., Lust S., Tam A., et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2011, 117(4):1311-1314.
157. Parveen I., Naughton D.P., Whish W.J., Threadgill M.D. 2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone. Bioorganic & Medicinal Chemistry Letters 1999, 9(14):2031-2036.
158. Patterson L.H., McKeown S.R., Ruparelia K., Double J.A., Bibby M.C., Cole S., et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. British Journal of Cancer 2000, 82(12):1984-1990.
159. Perez-Sayans M., Somoza-Martin J.M., Barros-Angueira F., Rey J.M., Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treatment Reviews 2009, 35(8):707-713.
160. Pinheiro C., Longatto-Filho A., Ferreira L., Pereira S.M., Etlinger D., Moreira M.A., et al. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. [Research Support, Non-U.S. Gov't]. International Journal of Gynecological Pathology 2008, 27(4):568-574.
161. Pinheiro C., Longatto-Filho A., Scapulatempo C., Ferreira L., Martins S., Pellerin L., et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Archives 2008, 452(2):139-146.
162. Pinheiro C., Sousa B., Albergaria A., Paredes J., Dufloth R., Vieira D., et al. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. [Research Support, Non-U.S. Gov't]. Histology and Histopathology 2011, 26(10):1279-1286.
163. Raghunand N., Gillies R.J. pH and drug resistance in tumors. Drug Resistance Updates 2000, 3(1):39-47.
164. Raghunand N., Howison C., Sherry A.D., Zhang S., Gillies R.J. Renal and systemic pH imaging by contrast-enhanced MRI. Magnetic Resonance in Medicine 2003, 49(2):249-257.
165. Raghunand N., Mahoney B., van Sluis R., Baggett B., Gillies R.J. Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 2001, 3(3):227-235.
166. Ramirez-Peinado S., Alcazar-Limones F., Lagares-Tena L., El Mjiyad N., Caro-Maldonado A., Tirado O.M., et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Research 2011.
167. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. [Research Support, U.S. Gov't, P.H.S.]. Cancer Research 2002, 62(15):4316-4324.
168. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. [Research Support, U.S. Gov't, P.H.S.]. Cancer Research 2004, 64(4):1475-1482.
169. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. [Research support, U.S. Gov't, P.H.S.]. Cancer Research 2004, 64(19):6845-6848.
170. Rastogi S., Banerjee S., Chellappan S., Simon G.R. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Letters 2007, 257(2):244-251.
171. Ravagnan L., Marzo I., Costantini P., Susin S.A., Zamzami N., Petit P.X., et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999, 18(16):2537-2546.
172. Rini B.I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clinical Cancer Research 2008, 14(5):1286-1290.
173. Rischin D., Peters L., Fisher R., Macann A., Denham J., Poulsen M., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology 2005, 23(1):79-87.
174. Rischin D., Peters L.J., O'Sullivan B., Giralt J., Fisher R., Yuen K., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology 2010, 28(18):2989-2995.
175. Robey I.F., Baggett B.K., Kirkpatrick N.D., Roe D.J., Dosescu J., Sloane B.F., et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Research 2009, 69(6):2260-2268.
176. Rofstad E.K. Microenvironment-induced cancer metastasis. International Journal of Radiation Biology 2000, 76(5):589-605.
177. Rofstad E.K., Mathiesen B., Kindem K., Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. [Research support, Non-U.S. Gov't]. Cancer Research 2006, 66(13):6699-6707.
178. Romero-Ramirez L., Cao H., Nelson D., Hammond E., Lee A.H., Yoshida H., et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Cancer Research 2004, 64(17):5943-5947.
179. Rouschop K.M., van den Beucken T., Dubois L., Niessen H., Bussink J., Savelkouls K., et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. [Research support, Non-U.S. Gov't]. Journal of Clinical Investigation 2010, 120(1):127-141.
180. Saito K., Matsumoto S., Devasahayam N., Subramanian S., Munasinghe J.P., Morris H.D., et al. Transient decrease in tumor oxygenation after intravenous administration of pyruvate. Magnetic Resonance in Medicine 2011.
181. Saito S., Furuno A., Sakurai J., Sakamoto A., Park H.R., Shin-Ya K., et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. [Research Support, Non-U.S. Gov't]. Cancer Research 2009, 69(10):4225-4234.
182. Santo L., Hideshima T., Kung A.L., Tseng J.C., Tamang D., Yang M., et al. Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012.
183. Schimmer A.D., Thomas M.P., Hurren R., Gronda M., Pellecchia M., Pond G.R., et al. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Research 2006, 66(4):2367-2375.
184. Schlappack O.K., Zimmermann A., Hill R.P. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. [Research support, Non-U.S. Gov't]. British Journal of Cancer 1991, 64(4):663-670.
185. Schwartz D.L., Powis G., Thitai-Kumar A., He Y., Bankson J., Williams R., et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Molecular Cancer Therapeutics 2009, 8(4):947-958.
186. Schwartz H.S., Sodergren J.E., Philips F.S. Mitomycin C: chemical and biological studies on alkylation. Science 1963, 142(3596):1181-1183.
187. Semenza G.L. Targeting HIF-1 for cancer therapy. [Review]. Nature Reviews Cancer 2003, 3(10):721-732.
188. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Maire P., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Journal of Biological Chemistry 1996, 271(51):32529-32537.
189. Seo M., Kim J.D., Neau D., Sehgal I., Lee Y.H. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the warburg effect. PLoS One 2011, 6(9):e24179.
190. Shen L.Z., Wang J.H., Wang H.Q., Hua Y.B., Wu W.X. Efficacy of antitumour colon cancer cell vaccine modified by Escherichia coli cytosine deaminase gene. Zhonghua Wei Chang Wai Ke Za Zhi 2006, 9(5):425-428.
191. Shepherd P.R., Kahn B.B. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. [Comment research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S. Review]. New England Journal of Medicine 1999, 341(4):248-257.
192. Silva A.S., Yunes J.A., Gillies R.J., Gatenby R.A. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Research 2009, 69(6):2677-2684.
193. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., Spitz D.R. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Research 2007, 67(7):3364-3370.
194. Singh D., Banerji A.K., Dwarakanath B.S., Tripathi R.P., Gupta J.P., Mathew T.L., et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005, 181(8):507-514.
195. Skeen J.E., Bhaskar P.T., Chen C.C., Chen W.S., Peng X.D., Nogueira V., et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006, 10(4):269-280.
196. Smith P.J., Blunt N.J., Desnoyers R., Giles Y., Patterson L.H. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. [Comparative study]. Cancer Chemotherapy and Pharmacology 1997, 39(5):455-461.
197. Song C.W., Clement J.J., Levitt S.H. Preferential cytotoxicity of 5-thio-D-glucose against hypoxic tumor cells. Journal of National Cancer Institute 1976, 57(3):603-605.
198. Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. [Research Support, Non-U.S. Gov't Review]. Radiotherapy & Oncology 2008, 86(3):300-313.
199. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Journal of Clinical Investigation 2008, 118(12):3930-3942.
200. Stacpoole P.W. The pharmacology of dichloroacetate. Metabolism 1989, 38(11):1124-1144.
201. Stacpoole P.W., Lorenz A.C., Thomas R.G., Harman E.M. Dichloroacetate in the treatment of lactic acidosis. Annals of Internal Medicine 1988, 108(1):58-63.
202. Stetak A., Lankenau A., Vantus T., Csermely P., Ullrich A., Keri G. The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. Biochemical and Biophysical Research Communications 2001, 285(2):483-488.
203. Stetak A., Veress R., Ovadi J., Csermely P., Keri G., Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Research 2007, 67(4):1602-1608.
204. Steward W.P., Middleton M., Benghiat A., Loadman P.M., Hayward C., Waller S., et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. [Clinical trial, Phase I research support, Non-U.S. Gov't]. Annals of Oncology 2007, 18(6):1098-1103.
205. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New England Journal of Medicine 1995, 333(9):550-554.
206. Sun J.D., Liu Q., Wang J., Ahluwalia D., Ferraro D., Wang Y., et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clinical Cancer Research 2012, 18(3):758-770.
207. Supuran C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. [Research support, Non-U.S. Gov't review]. Nature Reviews Drug Discovery 2008, 7(2):168-181.
208. Taverna R.D., Langdon R.G. Reversible association of cytochalasin B with the human erythrocyte membrane. Inhibition of glucose transport and the stoichiometry of cytochalasin binding. Biochimica et Biophysica Acta 1973, 323(2):207-219.
209. Thangaraju M., Karunakaran S.K., Itagaki S., Gopal E., Elangovan S., Prasad P.D., et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. [Research support, N.I.H., extramural]. Cancer 2009, 115(20):4655-4666.
210. Thorwarth D., Eschmann S.M., Holzner F., Paulsen F., Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiotherapy Oncology 2006, 80(2):151-156.
211. Tibes R.F.G.S., Von Hoff D.D., Weiss G.J., Iyengar T., Kurzrock R., Pestano L., et al. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. [Abstract]. Journal of Clinical Oncology 2010, 28.
212. Tiseo M., Bartolotti M., Gelsomino F., Ardizzoni A. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Review of Anticancer Therapy 2009, 9(4):425-435.
213. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research 2004, 64(11):3731-3736.
214. Travers K.J., Patil C.K., Wodicka L., Lockhart D.J., Weissman J.S., Walter P. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Cell 2000, 101(3):249-258.
215. Tureci O., Sahin U., Vollmar E., Siemer S., Gottert E., Seitz G., et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Proceedings of the National Academy of Sciences U S A 1998, 95(13):7608-7613.
216. Valk P.E., Mathis C.A., Prados M.D., Gilbert J.C., Budinger T.F. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. Journal of Nuclear Medicine 1992, 33(12):2133-2137.
217. Vantus T., Keri G., Krivickiene Z., Valius M., Stetak A., Keppens S., et al. The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases. Cell Signal 2001, 13(10):717-725.
218. Vaupel P. The role of hypoxia-induced factors in tumor progression. [Review]. Oncologist 2004, 9(Suppl. 5):10-17.
219. Vera J.C., Reyes A.M., Velasquez F.V., Rivas C.I., Zhang R.H., Strobel P., et al. Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry 2001, 40(3):777-790.
220. Vester B., Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. [Research support, Non-U.S. Gov't review]. Biochemistry 2004, 43(42):13233-13241.
221. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. Journal of Antibiotics (Tokyo) 1975, 28(10):721-726.
222. Volkmann K., Lucas J.L., Vuga D., Wang X., Brumm D., Stiles C., et al. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. [Research support, Non-U.S. Gov't]. Journal of Biological Chemistry 2011, 286(14):12743-12755.
223. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L.O., Clark P., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. Journal of Clinical Oncology 2000, 18(6):1351-1359.
224. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
225. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. Journal of General Physiology 1927, 8(6):519-530.
226. Weinhouse S. The Warburg hypothesis fifty years later. [Research support, U.S. Gov't, P.H.S.]. Zeitschrift für Krebsforschung und klinische Onkologie. Cancer Research and Clinical Oncology 1976, 87(2):115-126.
227. Weiss G.J., Infante J.R., Chiorean E.G., Borad M.J., Bendell J.C., Molina J.R., et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clinical Cancer Research 2011, 17(9):2997-3004.
228. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 2004, 3(3):233-244.
229. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiotherapy and Oncology 1984, 2(4):343-366.
230. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 2004, 10(2):145-147.
231. Willett C.G., Duda D.G., Ancukiewicz M., Shah M., Czito B.G., Bentley R., et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010, 15(8):845-851.
232. Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D.V., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. Journal of Clinical Oncology 2009, 27(18):3020-3026.
233. Williams K.J., Albertella M.R., Fitzpatrick B., Loadman P.M., Shnyder S.D., Chinje E.C., et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. [Research support, Non-U.S. Gov't]. Molecular Cancer Therapeutics 2009, 8(12):3266-3275.
234. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6(6):553-563.
235. Wojtkowiak J.W., Verduzco D., Schramm K.J., Gillies R.J. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Molecular Pharmacology 2011, 8(6):2032-2038.
236. Wong J.Y., Huggins G.S., Debidda M., Munshi N.C., De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecologic Oncology 2008, 109(3):394-402.
237. Wood T.E., Dalili S., Simpson C.D., Hurren R., Mao X., Saiz F.S., et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Molecular Cancer Therapeutics 2008, 7(11):3546-3555.
238. Xie H., Valera V.A., Merino M.J., Amato A.M., Signoretti S., Linehan W.M., et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Molecular Cancer Therapeutics 2009, 8(3):626-635.
239. Xie J., Wang B.S., Yu D.H., Lu Q., Ma J., Qi H., et al. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. International Journal of Oncology 2011, 38(2):409-417.
240. Yu Y., Deck J.A., Hunsaker L.A., Deck L.M., Royer R.E., Goldberg E., et al. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochemical Pharmacology 2001, 62(1):81-89.
241. Zagorevskii D., Song M., Breneman C., Yuan Y., Fuchs T., Gates K.S., et al. A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. Journal of the American Society for Mass Spectrometry 2003, 14(8):881-892.
242. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 2006, 66(21):10269-10273.
243. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology, Biology, Physics 1986, 12(7):1239-1242.
244. Zhang F., Aft R.L. Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. Jounal of Cancer Research and Therapeutics 2009, 5(Suppl 1):S41-43.
245. Zhang J., Tian Q., Yung Chan S., Chuen Li S., Zhou S., Duan W., et al. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metabolism Reviews 2005, 37(4):611-703.
246. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 2001, 108(8):1167-1174.
247. Zhou Y., Tozzi F., Chen J., Fan F., Xia L., Wang J., et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't research support, U.S. Gov't, Non-P.H.S.]. Cancer Research 2012, 72(1):304-314.